Sartorius Stedim Biotech 3-Year Book Growth Rate 22.40 percent - GuruFocus.com
| DIM Stock | EUR 192.75 0.90 0.47% |
About 53% of Sartorius Stedim's investor base is interested to short. The analysis of current outlook of investing in Sartorius Stedim Biotech suggests that many traders are impartial regarding Sartorius Stedim's prospects. The current market sentiment, together with Sartorius Stedim's historical and current headlines, can help investors time the market. In addition, many technical investors use Sartorius Stedim Biotech stock news signals to limit their universe of possible portfolio assets.
Sartorius |
Sartorius Stedim Biotech 3-Year Book Growth Rate 22.40 percent GuruFocus.com
Read at news.google.com
 |
Sartorius Stedim Fundamental Analysis
We analyze Sartorius Stedim's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sartorius Stedim using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sartorius Stedim based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Sartorius Stedim is currently under evaluation in current liabilities category among its peers. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Sartorius Stedim Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sartorius Stedim stock to make a market-neutral strategy. Peer analysis of Sartorius Stedim could also be used in its relative valuation, which is a method of valuing Sartorius Stedim by comparing valuation metrics with similar companies.
Peers
Sartorius Stedim Related Equities
| ALALO | Acheter Louer | 5.41 | ||||
| ALSGD | Spineguard | 4.55 | ||||
| ALBPS | Biophytis | 3.13 | ||||
| ALNEV | Neovacs SA | 10.00 |
Complementary Tools for Sartorius Stock analysis
When running Sartorius Stedim's price analysis, check to measure Sartorius Stedim's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sartorius Stedim is operating at the current time. Most of Sartorius Stedim's value examination focuses on studying past and present price action to predict the probability of Sartorius Stedim's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sartorius Stedim's price. Additionally, you may evaluate how the addition of Sartorius Stedim to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |